2024-11-08 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison:**

Merck & Co Inc (MRK) is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, biological therapies, and animal health products.

MRK's cumulative return is 56.24%, lagging behind the S&P 500 (VOO) with a cumulative return of 139.88%. This translates to a current performance gap of -83.64%, placing it at the 2.89th percentile of historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015-2017 | -1.6% | 18.1% | -31.8% | 0.9 |
| 2016-2018 | 45.6% | 17.0% | 20.9% | 0.7 |
| 2017-2019 | 51.2% | 17.0% | 8.1% | 0.7 |
| 2018-2020 | 45.5% | 27.2% | 6.4% | 0.7 |
| 2019-2021 | 6.3% | 27.2% | -83.6% | 0.6 |
| 2020-2022 | 26.3% | 27.2% | 8.6% | 0.5 |
| 2021-2023 | 41.1% | 19.8% | 12.3% | 0.3 |
| 2022-2024 | 31.0% | 23.2% | 7.3% | 0.3 |

The analysis reveals that MRK has generally underperformed the market, with negative alpha values in most periods. However, its beta value consistently below 1 indicates lower volatility compared to the market.

**2. Recent Price Movement:**

* Closing Price: 100.73
* Last Market: 101.36
* 5-day Moving Average: 101.69
* 20-day Moving Average: 105.98
* 60-day Moving Average: 111.99

MRK's current price is below its 5-day, 20-day, and 60-day moving averages, suggesting a downward trend in the short-term.

**3. Technical Indicators:**

* RSI: 13.39 - This indicates an oversold condition, potentially suggesting a rebound in the near term.
* PPO: -0.3 - This suggests a weak price momentum, supporting the downward trend.
* Delta_Previous_Relative_Divergence: -18.41 - This signifies a short-term decline in relative price movement, aligning with the overall downward trend.
* Expected Return: 0.0% - This indicates that long-term, consistent investment in MRK is unlikely to generate outperformance compared to the S&P 500.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

MRK's most recent earnings report shows an EPS of 1.25 and revenue of $16.66B, exceeding analyst expectations. 

**5. Financial Information:**

1) **Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

MRK has consistently demonstrated strong revenue growth and high profit margins, showcasing its solid financial position and profitability.

2) **Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |

MRK demonstrates robust equity growth and a generally stable ROE, suggesting good capital management and profitability.

**6. News and Recent Developments:**

* **Recent Earnings News:** MRK's most recent earnings call, reported on 2024-11-06, displayed strong revenue growth and a beat on EPS expectations, supported by continued strong performance from the Keytruda franchise. 

* **Market Outlook:** The market outlook for MRK remains positive, with analysts highlighting the company's strong pipeline of new drugs and its leadership position in oncology and other therapeutic areas.

* **Analyst Opinions and Performance Highlights:**  Finbold reported that MRK received an average target price of $128.48, with a potential upside of 27.46%. The strong financial performance, growth prospects, and stable dividend payout have encouraged many analysts to maintain a positive outlook.

**7. Overall Analysis:**

MRK, although currently lagging behind the market, exhibits a strong financial foundation with consistent revenue growth, healthy profit margins, and a stable ROE. Its recent earnings beat and positive market outlook further suggest potential for future growth. However, its recent price action and technical indicators suggest a short-term downtrend. 

Long-term investors may find value in MRK, especially given its focus on innovative drug development and strong performance in key therapeutic areas. However, given the current price trend and expected return, it is crucial to monitor the stock closely and adjust investment strategy based on evolving market conditions.

**Please note:** This report is for informational purposes only and should not be considered financial advice. It is essential to conduct your own research and consult with a financial advisor before making any investment decisions.